The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Evdoshenko E.P.

Sankt-Peterburgskoe GBUZ "Gorodskaia klinicheskaia bol'nitsa #31", Sankt-Peterburgskiĭ gorodskoĭ Tsentr rasseiannogo skleroza i autoimmunnykh zabolevaniĭ, Sankt-Peterburg

Vorob'eva O.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ

You X.

Biogen, Cambridge, MA, USA

Pukaite V.

Biogen, International GmbHh, Zug, Switzerland

A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis

Authors:

Boĭko A.N., Evdoshenko E.P., Vorob'eva O.V., You X., Pukaite V.

More about the authors

Views: 1682

Downloaded: 32


To cite this article:

Boĭko AN, Evdoshenko EP, Vorob'eva OV, You X, Pukaite V. A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(8‑2):25‑35. (In Russ.)
https://doi.org/10.17116/jnevro20151158225-35

Recommended articles:
Effi­cacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):69-79

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.